Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00051168 | A Long-term Safety Study of Once-daily Travatan | PHASE3 | COMPLETED | 502 | — | — | Jan 1, 2006 | - | Oct 7, 2011 | 1 | United States |
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
| Arm | Type | Description |
|---|---|---|
| Travatan | EXPERIMENTAL | Travoprost (0.004%) |
| Name | Type | Description |
|---|---|---|
| Travatan | DRUG | Travoprost (0.004%) 1 drop each eye once daily |
Adult patients of any race and either sex with chronic angle-closure glaucoma.